What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus (HSV-1) expressing the human collagen VII protein”In the company’s words, NCT07016750 on ClinicalTrials.gov
- Tested for
- Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Main trialPhase 3
- “KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).”In the company’s words, NCT07016750 on ClinicalTrials.gov
Other drugs for Dystrophic Epidermolysis Bullosa
- D-FiCastle Creek Biosciences, LLC. · Phase 3
- FCX-007Castle Creek Biosciences, LLC. · Phase 3
- Oleogel-S10Chiesi Farmaceutici S.p.A. · Phase 3
- ENERGI-F703Energenesis Biomedical Co., Ltd. · Phase 2
- TCP-25 gelXinnate AB · Phase 2
- AGLE-102Aegle Therapeutics · Phase 1/2
Coming up1
- DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Dec 2026 | A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026